Induced Pluripotent Stem Cells: How iPSCs Are Made and Used

Added:

Limitations of iPSCs: Epigenetic Memory, Genomic Instability, and Tumorigenic Risk

While induced pluripotent stem cells (iPSCs) offer a revolutionary, ethically uncomplicated alternative to embryonic stem cells (ESCs), significant scientific concerns persist regarding their equivalence and safety. A major limitation is 'epigenetic memory,' where iPSCs retain molecular markers from their donor adult cells, biasing their differentiation potential and compromising their accuracy in disease modeling. Furthermore, the reprogramming process can induce genomic instability, leading to DNA mutations, copy number variations, and chromosomal aberrations. The use of reprogramming factors—some of which are known oncogenes (like c-Myc)—combined with these genetic alterations raises substantial risks of tumorigenicity (cancer development) when iPSCs are used in clinical cell therapies. Consequently, many researchers argue that ESCs remain the essential 'gold standard' for pluripotency, and that iPSCs are not yet a flawless or complete replacement for therapeutic and research applications.

Basic stem cell biology, specifically the definitions of pluripotency, multipotency, and cellular differentiation.
The central dogma of molecular biology, including how transcription factors bind to DNA to regulate gene expression.
The concept of epigenetic regulation, including how DNA methylation and histone modification determine cell-type identity without altering the genetic sequence.
The fundamental differences between somatic (adult) cells and embryonic stem cells (ESCs).
The specific molecular mechanisms of the Yamanaka factors (Oct4, Sox2, Klf4, and c-Myc) in achieving pluripotency.
The generation and application of 3D organoids derived from iPSCs for advanced, patient-specific disease modeling.
The translation of iPSC technology into clinical trials, including challenges like tumorigenicity (teratoma formation) and genomic instability.
The integration of CRISPR/Cas9 gene editing with iPSCs to create isogenic cell lines for precise drug discovery and gene therapy.
5.5K views142likes4:18@ioanatheiguana2990Original Release: 2022-09-01

Induced pluripotent stem cells (iPSCs) are created by reprogramming adult cells (such as skin or hair follicle cells) back to an embryonic-like pluripotent state using four transcription factors (Oct34, Klf4, c-Myc, and Sox2), known as the Yamanaka factors, which allows these cells to be differentiated into any desired cell type for potential applications in regenerative medicine, drug testing, and disease treatment.